

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Medtide Inc.

泰德醫藥(浙江)股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 3880)

PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION OF THE COMPANY AND ABOLISHMENT OF THE SUPERVISORY COMMITTEE

The Board (the “**Board**”) of Directors (“**Director(s)**”) of Medtide Inc. (the “**Company**”) hereby announces that on March 30, 2026, the Board passed resolutions in relation to, among others, the proposed amendments to the Articles of Association of the Company and abolishment of the Supervisory Committee.

PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION OF THE COMPANY AND ABOLISHMENT OF THE SUPERVISORY COMMITTEE

On December 29, 2023, the amendments to the Company Law of the People's Republic of China (《中華人民共和國公司法》) (the “**PRC Company Law**”) was adopted, which came into effect on July 1, 2024. The amendments introduced by the new PRC Company Law include but not limited to reforming the corporate capital system and organizational structure, enhancement in protection for minority shareholders' rights and interests, strengthening responsibilities for controlling shareholders, directors and senior management as well as permitting the replacement of supervisory committee with audit committee. In order to ensure the listed companies can effectively comply with and implement the new requirements of the PRC Company Law, the China Securities Regulatory Commission issued a number of important documents on March 28, 2025, including the revised Guidelines on the Articles of Association of Listed Companies (《上市公司章程指引》).

In light of the above, the Board proposed to make certain amendments to its existing articles of association of the Company (the “**Articles of Association**”), mainly including but not limited to (1) the abolishment of the supervisory committee of the Company (the “**Supervisory Committee**”) and the exercise of its functions and powers by the audit committee of the Board as stipulated by the PRC Company Law; (2) enhancing protection for Shareholders' (the “**Shareholders**”) rights; (3) consequential amendments to the provisions of the Articles of Association in accordance with changes in applicable laws and regulations; and (4) other internal affairs and miscellaneous changes (the “**Proposed Amendments to the Articles of Association**”).

Each supervisor of the Company has confirmed that he/she has no disagreement with the Supervisory Committee and that there is no other matter in relation to his/her resignation that needs to be brought to the attention of the Shareholders.

According to the Articles of Association and the relevant laws and regulations, the proposed amendments to the Articles of Association will take effect subject to the approval of the Shareholders at the forthcoming annual general meeting (the “AGM”) by way of special resolution. A special resolution in relation to the proposed amendments to the Articles of Association will be proposed at the AGM for the approval by the Shareholders. A circular of the Company containing, further details of the proposed amendments to the Articles of Association of the Company and abolishment of the Supervisory Committee will be published on the websites of the Stock Exchange (www.hkexnews.hk) and the Company (www.medtideinc.com) in due course.

By order of the Board
Medtide Inc.
泰德醫藥(浙江)股份有限公司
Dr. Xu Qi
Chairwoman and Chief Executive Officer

Hong Kong, March 30, 2026

As at the date of this announcement, the executive Directors of the Company are Dr. Xu Qi (徐琪), Dr. Li Xiang (李湘), Ms. Li Xiangli (李湘莉), Ms. Cheng Tao and Ms. Li Lingmei (李玲梅); the non-executive Director of the Company is Mr. Wu Yihui (吳一暉); and the independent non-executive Directors of the Company are Dr. Yu Cheung Hoi (于常海), Dr. Zhu Xun (朱迅) and Mr. Xia Xinsheng (夏心晟).